Tarlatamab maintenance for limited-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new immunotherapy medicine called tarlatamab given as maintenance therapy after initial treatment for limited-stage small cell lung cancer. It aims to keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have limited-stage small cell lung cancer (cancer only in one lung and nearby lymph nodes)
- You have finished chemotherapy with or without radiation, and your cancer did not get worse during that treatment
- You are 18 years or older
- You are in generally good health (able to do daily activities, with some help if needed)
- You do not have significant lung, heart, or immune problems (like interstitial lung disease, recent heart attack, or active infections)
- You have no history of other cancers (unless it was successfully treated and you have been cancer-free for at least 3 years)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new drug called tarlatamab to a standard immunotherapy (durvalumab) works better than durvalumab alone for small cell lung cancer that hasn't spread widely. You would be eligible if you've already completed chemotherapy and radiation therapy and your cancer hasn't gotten worse.
This trial tests a new drug called tarlatamab, given either as an injection under the skin or through an IV, for people with extensive-stage small cell lung cancer that has grown or come back after one round of chemotherapy. The goal is to see which way of giving the drug works better and is safer.
This trial tests an experimental drug called tarlatamab for people newly diagnosed with extensive-stage small-cell lung cancer (SCLC). The goal is to see if tarlatamab can help shrink or control the cancer.
This trial tests a new drug called tarlatamab for people with advanced small cell lung cancer that has worsened after one prior round of chemotherapy plus immunotherapy. It's designed for patients who are still active but may need extra support (ECOG 2).
This trial tests a new drug called tarlatamab for people with advanced small cell or neuroendocrine cancers that started outside the lung (like in the stomach, bladder, or head and neck) and have grown after initial chemotherapy. It aims to see if this treatment can shrink or control the cancer.
This trial tests a new drug, tarlatamab, for people with small cell lung cancer that has spread to the brain. It aims to see if the drug can shrink brain tumors and help you live longer, especially if you have not had brain radiation before.
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.